Baseline characteristics and results of 12 newly diagnosed ITP patients treated with a single course of high-dose dexamethasone and eltrombopag
| N . | Age, y/sex . | Type of bleeding . | Bleeding grade . | Time to PR/CR . | Day 5 . | Day 34 . | Month 3 . | Month 6 . | DOR, wk . | Relapse . | Follow-up, mo . | Current status . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 38/F | He/Gu/Ep | 2 | –/5 | CR | CR | CR* | CR* | 6.5 | Yes | 18 | CR* |
| 2 | 49/F | Ec/Me | 2 | –/5 | CR | CR | PR | PR | 72 | — | 17 | PR |
| 3 | 40/F | Ec/Gu | 1 | –/5 | CR | CR | CR | CR | 68 | — | 16 | CR |
| 4 | 20/M | Ec | 2 | 12/26 | NR | CR | PR | PR | 58.5 | — | 14 | PR |
| 5 | 60/M | He | 2 | 19/26 | NR | PR | PR | PR | 57.6 | — | 14 | PR |
| 6 | 68/F | Pe/Gu/Re | 2 | –/5 | CR | CR | CR | CR | 55 | — | 13 | CR |
| 7 | 79/F | Pe/Gu/Ep | 2 | 5/19 | PR | CR | PR* | PR* | 8 | Yes | 12 | PR* |
| 8 | 40/F | Pe/Ec/Ep | 1 | 5/34 | PR | CR | PR | CR | 37.8 | — | 9 | CR |
| 9 | 80/M | Pe/Hem | 3 | –/5 | CR | CR | CR | CR* | 20.6 | Yes | 8 | CR* |
| 10 | 68/M | He | 2 | 5/19 | PR | CR | CR | CR | 33.5 | — | 8 | CR |
| 11 | 30/M | Pe/Ec/Ep | 2 | 5/26 | PR | CR | CR | CR | 29.4 | — | 7 | CR |
| 12 | 51/M | Pe/He | 2 | 5/12 | PR | PR | CR | CR | 29.4 | Yes | 7 | SD* |
| N . | Age, y/sex . | Type of bleeding . | Bleeding grade . | Time to PR/CR . | Day 5 . | Day 34 . | Month 3 . | Month 6 . | DOR, wk . | Relapse . | Follow-up, mo . | Current status . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 38/F | He/Gu/Ep | 2 | –/5 | CR | CR | CR* | CR* | 6.5 | Yes | 18 | CR* |
| 2 | 49/F | Ec/Me | 2 | –/5 | CR | CR | PR | PR | 72 | — | 17 | PR |
| 3 | 40/F | Ec/Gu | 1 | –/5 | CR | CR | CR | CR | 68 | — | 16 | CR |
| 4 | 20/M | Ec | 2 | 12/26 | NR | CR | PR | PR | 58.5 | — | 14 | PR |
| 5 | 60/M | He | 2 | 19/26 | NR | PR | PR | PR | 57.6 | — | 14 | PR |
| 6 | 68/F | Pe/Gu/Re | 2 | –/5 | CR | CR | CR | CR | 55 | — | 13 | CR |
| 7 | 79/F | Pe/Gu/Ep | 2 | 5/19 | PR | CR | PR* | PR* | 8 | Yes | 12 | PR* |
| 8 | 40/F | Pe/Ec/Ep | 1 | 5/34 | PR | CR | PR | CR | 37.8 | — | 9 | CR |
| 9 | 80/M | Pe/Hem | 3 | –/5 | CR | CR | CR | CR* | 20.6 | Yes | 8 | CR* |
| 10 | 68/M | He | 2 | 5/19 | PR | CR | CR | CR | 33.5 | — | 8 | CR |
| 11 | 30/M | Pe/Ec/Ep | 2 | 5/26 | PR | CR | CR | CR | 29.4 | — | 7 | CR |
| 12 | 51/M | Pe/He | 2 | 5/12 | PR | PR | CR | CR | 29.4 | Yes | 7 | SD* |
CR, Plt ≥100 × 109/L; Ec, ecchymoses; Ep, epistaxis; F, female; Gu, gum; He, hematomas; Hem, hematuria; M, male, Me, menorrhagia; N, patient number; NR, no response; Pe, petechiae; PR, response was defined as platelets 30 to <100 × 109/L and doubling from baseline; Re, rectorrhagia; SD, stable disease.
Patients had previously relapsed. Results are shown after treatment with high-dose dexamethasone and low-dose rituximab.